Compugen to Discuss AI-Driven Drug Discovery at H.C. Wainwright Conference
Event summary
- Compugen to participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference on October 8, 2026, at 9:30 AM ET.
- The event will be held virtually and a replay will be available post-event.
- Compugen's pipeline includes COM701, rilvegostomig, and GS-0321, with partnerships with AstraZeneca and Gilead.
- COM701 is being evaluated in the MAIA-ovarian trial for relapsed platinum-sensitive ovarian cancer.
- Rilvegostomig is being developed by AstraZeneca and is in multiple Phase 3, Phase 2, and Phase 1 clinical trials.
The big picture
Compugen's participation in the H.C. Wainwright conference underscores the growing importance of AI in drug discovery, particularly in the immuno-oncology space. The company's strategic partnerships with AstraZeneca and Gilead highlight its ability to leverage computational platforms for novel therapeutic development. The success of its clinical trials will be critical in determining its long-term market position and investor appeal.
What we're watching
- Clinical Progress
- How the MAIA-ovarian trial for COM701 will impact Compugen's valuation and strategic partnerships.
- Partnership Dynamics
- Whether AstraZeneca's development of rilvegostomig will lead to further collaborations or licensing deals.
- Market Positioning
- The pace at which Compugen can differentiate itself in the competitive AI-driven drug discovery space.
Related topics